Investing.comQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 19:08:33·⟳ 抓取 19:09:32 +59s·⚡ 决策 09-02 19:13:38 +4m06s·55.3 天前
Bausch + Lomb 发布 enVista Aspire 人工晶体小样本回顾性研究结果
这是一篇已上市人工晶体产品的84例小样本回顾性病例系列研究发表，属于常规营销/临床证据生成活动，不含任何新增监管批准、新产品上市、收入指引变化或市场准入等实质性增量信息，对 Bausch + Lomb 的盈利预期和估值无可量化影响，不构成可交易事件。
📄 原文Investing.com↗ 原文
Bausch + Lomb study shows enVista Aspire lenses improve vision
Oil prices rise for third session as US-Iran tensions fuel supply concerns VAUGHAN, Ontario - Bausch + Lomb Corporation…
不做 Bausch + Lomb（BLCO.US）
已上市产品的小样本回顾性研究发表（84例/141眼），属于常规营销证据生成，无新增监管批准、新适应症、新市场或收入指引变化，对大市值公司无实质性盈利增量，不构成可交易催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Bausch + Lomb 发布 enVista Aspire 人工晶体的小样本回顾性研究（84例/141眼），该产品已上市销售。研究结果良好但属于已上市产品的常规临床证据补充，无新增监管里程碑、无新适应症获批、无收入指引变化。对于大市值医疗器械公司，此类低证据级别的回顾性研究发表不构成股价催化剂，无正期望交易机会。
🔎 新鲜度:最早出现 2026-09-02 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例校准，事件本身不构成可交易催化
方向:不适用
涨幅量级:不适用
形态:不适用
原文全文
展开原文 · 1,901 字
Oil prices rise for third session as US-Iran tensions fuel supply concerns
VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX:BLCO) announced today the publication of a study examining real-world outcomes of its enVista Aspire and enVista Aspire toric intraocular lenses in cataract surgery patients.
The multicenter retrospective case series, published in Ophthalmology and Therapy, included 84 patients and 141 eyes across six U.S.-based surgical centers. The study evaluated corrected and uncorrected distance visual acuity, uncorrected intermediate visual acuity, refractive outcomes and safety, according to a press release statement.
In the enVista Aspire patient group, 97.2% achieved monocular corrected distance visual acuity of 20/25 or better, while 71.3% attained monocular uncorrected distance visual acuity of 20/25 or better. Additionally, 76.6% reached monocular uncorrected intermediate visual acuity of 20/32 or better.
For the enVista Aspire toric group, 94.9% reached monocular corrected distance visual acuity of 20/25 or better, 84.9% achieved monocular uncorrected distance visual acuity of 20/25 or better, and 93% attained monocular uncorrected intermediate visual acuity of 20/32 or better. All subjects in both groups achieved binocular uncorrected intermediate visual acuity of 20/32 or better.
The study reported no serious adverse events.
The enVista Aspire lenses use an optical modification of the posterior aspheric surface to create a small continuous increase in lens power within the central 1.5 mm diameter. The enVista Aspire toric lenses are designed for patients with corneal astigmatism.
Dr. Eric Donnenfeld, lead author and ophthalmologist with Ophthalmic Consultants of Connecticut, stated the outcomes mirror his clinical practice experience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX:BLCO) announced today the publication of a study examining real-world outcomes of its enVista Aspire and enVista Aspire toric intraocular lenses in cataract surgery patients.
The multicenter retrospective case series, published in Ophthalmology and Therapy, included 84 patients and 141 eyes across six U.S.-based surgical centers. The study evaluated corrected and uncorrected distance visual acuity, uncorrected intermediate visual acuity, refractive outcomes and safety, according to a press release statement.
In the enVista Aspire patient group, 97.2% achieved monocular corrected distance visual acuity of 20/25 or better, while 71.3% attained monocular uncorrected distance visual acuity of 20/25 or better. Additionally, 76.6% reached monocular uncorrected intermediate visual acuity of 20/32 or better.
For the enVista Aspire toric group, 94.9% reached monocular corrected distance visual acuity of 20/25 or better, 84.9% achieved monocular uncorrected distance visual acuity of 20/25 or better, and 93% attained monocular uncorrected intermediate visual acuity of 20/32 or better. All subjects in both groups achieved binocular uncorrected intermediate visual acuity of 20/32 or better.
The study reported no serious adverse events.
The enVista Aspire lenses use an optical modification of the posterior aspheric surface to create a small continuous increase in lens power within the central 1.5 mm diameter. The enVista Aspire toric lenses are designed for patients with corneal astigmatism.
Dr. Eric Donnenfeld, lead author and ophthalmologist with Ophthalmic Consultants of Connecticut, stated the outcomes mirror his clinical practice experience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。